AstraZeneca's speedy trial restart splits experts
By MYBRANDBOOK
With the European Medicines Agency (EMA) announcing today that it will also initiate a rolling review of the COVID-19 vaccine developed by Pfizer and BioNTech besides just AstraZeneca’s asset;
Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his view:
“After interviewing ten experts, there is clearly a split in terms of whether AstraZeneca’s COVID-19 vaccine AZD1222 trials restarted too quickly on the heels of news reports of a trial volunteer having transverse myelitis. With regards to the other vaccine frontrunners, Pfizer and BioNTech’s trial design may have an edge in reporting data earlier - yet Moderna’s may offer data granularity to help decisions as to who should be prioritized for a jab.
“With regards to AstraZeneca’s ongoing trial pause in the US, while some experts agreed with the FDA that more in-depth analysis is needed to conclude these events are truly independent of the vaccine, others noted these cases are unprecedented with the vaccine’s adenovirus vector and so could be due to chance.
“The FDA has broadened its investigations and still has the US trial on hold. Yet, on 1 October, the EMA announced it was starting a rolling review of AZD1222, and after the company confirming on 9 September it had paused its global AZD1222 investigations, all ex-US trials have now restarted, including in Brazil, Japan and South Africa, as well as the UK, where two neurological events occurred in two separate trials.
“However, several experts noted there should be more scrutiny over whether the process has had enough time to properly evaluate if more neurological events could occur later in the trial or in the general population. The first event that triggered an AstraZeneca trial pause was multiple sclerosis, which was concluded as not caused by the vaccine, yet is in the same neurological disease ballpark as transverse myelitis. But other experts noted the vaccine’s cost-benefit ratio would deserve more scrutiny only if there were more of the same events in the trials.
In general, interviewed experts cautioned that any COVID-19 vaccine receiving an Emergency Use Authorization (EUA) from the FDA based on interim analysis data is unlikely to offer detailed information about which subpopulations the authorized vaccine is best suited for.
“Pfizer and BioNTech’s late-phase BNT162b2 trial is designed to report interim data earlier than others in the race and has the potential for a broader label than Moderna’s mRNA-1273 vaccine, which is also based on mRNA technology like BNT162b2. Yet, Pfizer and BioNTech’s early results could leave vaccinators unclear about which patient group would be best suited to use the vaccine.
“Such detail is crucial considering initial vaccine supply is expected to be limited and so would need to be prioritized for distribution. Prioritization discussions is recently in front of mind in the UK, with the head of the UK’s vaccine task force noting that less than half of the UK population is to receive a COVID-19 vaccine.”
BREAKING NEWS
TECHNO TRENDS
Legal Battle Over IT Act Intensifies Amid Musk’s India Plans
The outcome of the legal dispute between X Corp and the Indian government c...
Wipro inks 10-year deal with Phoenix Group's ReAssure UK worth
The agreement, executed through Wipro and its 100% subsidiary,...
Centre announces that DPDP Rules nearing Finalisation by April
The government seeks to refine the rules for robust data protection, ensuri...
Home Ministry cracks down on PoS agents in digital arrest scam
Digital arrest scams are a growing cybercrime where victims are coerced or ...
E-Magazine
TECHNOTAINMENT
Hrithik Roshan to endorse RuPay as Brand Ambassador
RuPay is reportedly planning to feature Bollywood superstar Hrithik Rosha
India Today Group launches – AI Pop Stars
Staying true to our industry leadership position in using cutting-edge tech
MOVERS & SHAKERS
TelioLabs ropes in Phaniraj V A as the Group CEO
TelioLabs has announced the onboarding of Phaniraj V A as its new Group CE
Wipro Appoints Amit Kumar as Managing Partner and Global Head
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology s
OPEN YOUR EYES
INTERVIEWS
Acer addresses evolving customer needs by consistently pushing
Acer offers a comprehensive range of products under one roof, including des
Alcatel-Lucent Enterprise Carrying a 100 year legacy ahead
A good amount of R&D works and global support services are operated out of
HOT PICK
MSI Announces the availability of RTX 50 series of laptops in
MSI, the innovative computing manufacturer in gaming, creator
Nothing Phone (3a) goes on sale today, starting at Rs 19,999
The phone was launched on March 4, featuring a 50MP main, ultra-wide, and t
MAKE IN INDIA BRANDS
TEJAS NETWORKS INDIA PVT. LTD.
SAMSUNG INDIA ELECTRONICS LTD.
VVDN TECHNOLOGIES
LAVA INTERNATIONAL LTD.
EMINENT CIO'S OF INDIA
ICONS OF INDIA
Icons Of India : NANDAN NILEKANI
Nandan Nilekani is the Co-Founder and Chairman of Infosys Technologies...
Icons Of India : Bhavish Aggarwal
Indian entrepreneur Bhavish Aggarwal is the CEO of Ola, India’s larg...
Icons Of India : Arjun Malhotra
Arjun Malhotra, the Chairman of Magic Software Inc., is widely recogni...
PARTNER SPEAKERS
PSU
CSC - Common Service Centres
CSC initiative in India is a strategic cornerstone of the Digital Indi...
RailTel Corporation of India Limited
RailTel is a leading telecommunications infrastructure provider in Ind...
ITI - ITI Limited
ITI Limited is a leading provider of telecommunications equipment, sol...
VIDEOS
Top 25 Brands
Global Indian industry
Indian Tech Talent Excelling The Tech World - Vinod Dham, Founder & Executive Managing Partner, IndoUS Venture Partners
Vinod Dham, known as the “Father of the Pentium Chip,” has left an...
Indian Tech Talent Excelling The Tech World - Thomas Kurian, CEO- Google Cloud
Thomas Kurian, the CEO of Google Cloud, has been instrumental in expan...
Indian Tech Talent Excelling The Tech World - Dheeraj Pandey, CEO, DevRev
Dheeraj Pandey, Co-founder and CEO at DevRev , has a remarkable journe...
ITFORUM 2025
CMO of the Year
WOMEN LEADERSHIP
IMAGE GALLERY
TRENDS IN TECHNOLOGY
MORE VIDEOS
ADVERTISEMENTS
TECHNOLOGY DISRUPTION
UNICORNS REVOLUTIONISING
of images belongs to the respective copyright holders
